FDA approves Biktarvy label update with data for pregnant adults with HIV
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated